Albumin-Bound Paclitaxel is named as an intervention in 35 current clinical trials in our China, USA and UK registers. 20 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chinese PLA General Hospital (3). The most-studied condition is Pancreatic Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Cancer | 5 |
| Gastric Cancer | 4 |
| Biliary Tract Cancer | 2 |
| Breast Cancer | 2 |
| Head and Neck Squamous Cell Carcinoma | 2 |
| Neoadjuvant Therapy | 2 |
| Cervical Cancer | 2 |
| Melanoma, Cutaneous Malignant | 1 |
| Advanced Cancer | 1 |
| Gastroesophageal-junction Cancer | 1 |
| Advanced Triple Negative Breast Cancer | 1 |
| Triple-negative Breast Cancer | 1 |
| Esophageal Cancer | 1 |
| Chemoradiotherapy | 1 |
| Albumin-bound Paxlitaxel | 1 |
| Unresectable Malignant Neoplasm | 1 |
| Early Breast Cancer | 1 |
| TNBC, Triple Negative Breast Cancer | 1 |
| Squamous Cell Non-small Cell Lung Cancer | 1 |
| Salivary Gland Carcinoma | 1 |
| Precision Therapy | 1 |
| HER2 Positive Advanced Solid Tumors | 1 |
| GC/GEJC | 1 |
| Second-line Treatment | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Neoadjuvant Chemotherapy | 1 |
| Bulky Neoplasm | 1 |
| Triple Negative Breast Cancer | 1 |
| Oral Cancer | 1 |
| Solid Tumor | 1 |
| Locally Advanced Cervical Cancer | 1 |
| Advanced Pancreatic Cancers | 1 |
| Tongue Squamous Cell Carcinoma | 1 |
| Gastric Cancer Peritoneal Metastasis (GCPM) | 1 |
| Solid Cancer | 1 |
| Uterine Cervical Neoplasm | 1 |
| Uterine Cervical Cancer | 1 |
| Oral Squamous Cell Carcinoma | 1 |
| Oropharyngeal Squamous Cell Carcinoma | 1 |
| Second Line Treatment | 1 |
| Chemotherapy | 1 |
| Tyrosine Kinase Inhibitor | 1 |
| Advanced or Metastatic Solid Tumors | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lead sponsor | Trials |
|---|---|
| Chinese PLA General Hospital | 3 |
| Sun Yat-sen University | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Fudan University | 2 |
| Immatics US, Inc. | 1 |
| Transcenta Therapeutics (Hangzhou) Co., Ltd. | 1 |
| AstraZeneca | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Fujian Cancer Hospital | 1 |
| Beijing Tongren Hospital | 1 |
| The First Affiliated Hospital of Bengbu Medical University | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Peking Union Medical College | 1 |
| InxMed (Shanghai) Co., Ltd. | 1 |
+ 14 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 32 | 19 |
| Clinical trials in USA | 3 | 1 |
| Clinical trials in UK | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
35 current trials in our China, USA and UK registers name Albumin-Bound Paclitaxel (also registered as 2 cycles) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 20 of the 35 trials are recruiting: 19 with sites in China, 1 with sites in USA and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Chinese PLA General Hospital (3), Sun Yat-sen University (3), Tianjin Medical University Cancer Institute and Hospital (2) and Fudan University (2), among 29 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Albumin-Bound Paclitaxel works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Albumin-Bound Paclitaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Albumin-Bound Paclitaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.